12:00 AM
 | 
Mar 05, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

UX003 regulatory update

FDA granted Orphan Drug designation for Ultragenyx's UX003 to treat mucopolysaccharidosis VII (MPS VII), an ultra-rare genetic lysosomal storage disease resulting...

Read the full 82 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >